Comparison table
Master Peptide Dosage Chart
Every protocol in the library on one screen. Sorted alphabetically, filterable by type, and searchable by name or use case.
| Peptide | Type | Dose range | Route | Frequency | Vial | Water | mg/mL |
|---|---|---|---|---|---|---|---|
| Adamax (10 mg Vial) | Single Peptide | 300-1000 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| AOD-9604 (10 mg Vial) | Single Peptide | 300-500 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| Ara-290 (16 mg Vial) | Single Peptide | 2-4 mg daily | Subcutaneous | Once daily | 16 mg | 3 mL | 5.33 |
| BPC-157 (10 mg Vial) | Single Peptide | 200-600 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| BPC-157 (5 mg Vial) | Single Peptide | 200-600 mcg daily | Subcutaneous | Once daily | 5 mg | 3 mL | 1.67 |
| Cagrilintide (10 mg Vial) | Single Peptide | 0.3-4.5 mg weekly | Subcutaneous | Once weekly | 10 mg | 3 mL | 3.33 |
| Cagrilintide (5 mg Vial) | Single Peptide | 0.3-4.5 mg weekly | Subcutaneous | Once weekly | 5 mg | 3 mL | 1.67 |
| CJC-1295 NO DAC + Ipamorelin (10 mg + 10 mg Blend) | Blend | 100-300 mcg each peptide daily | Subcutaneous | Once daily | 20 mg | 3 mL | 6.67 |
| DSIP (10 mg Vial) | Single Peptide | 100-300 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| Eloralintide (10 mg Vial) | Single Peptide | 1-9 mg weekly | Subcutaneous | Once weekly | 10 mg | 3 mL | 3.33 |
| Epitalon (50 mg Vial) | Single Peptide | 5 mg daily | Subcutaneous | Once daily for 20 days | 50 mg | 3 mL | 16.67 |
| GHK-Cu (100 mg Vial) | Single Peptide | 1.0-2.0 mg per injection | Subcutaneous | Once daily (5 days/week) or 3 times weekly | 100 mg | 3 mL | 33.33 |
| GHK-Cu (50 mg Vial) | Single Peptide | 1.0-2.0 mg per injection | Subcutaneous | 3 to 5 times weekly | 50 mg | 3 mL | 16.67 |
| GLOW (70 mg Blend) | Blend | 2,330 mcg daily | Subcutaneous | Once daily | 70 mg | 3 mL | 23.3 |
| Glutathione (1500 mg Vial) | Single Peptide | 100-200 mg daily | Subcutaneous | Once daily or every other day | 1500 mg | 3 mL | 500 |
| IGF-1 LR3 (1 mg Vial) | Single Peptide | 20-50 mcg daily | Subcutaneous | Once daily | 1 mg | 3 mL | 0.333 |
| Ipamorelin (10 mg Vial) | Single Peptide | 100-300 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| KLOW (80 mg Blend) | Blend | 250-750 mcg daily | Subcutaneous | Once daily | 80 mg | 3 mL | 26.67 |
| KPV (10 mg Vial) | Single Peptide | 200-500 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| Mazdutide (10 mg Vial) | Single Peptide | 2-6 mg weekly | Subcutaneous | Once weekly | 10 mg | 3 mL | 3.33 |
| Melanotan I (10 mg Vial) | Single Peptide | 0.5-1 mg daily (loading), then 0.5-1 mg 1-2x weekly | Subcutaneous | Daily during loading; once or twice weekly for maintenance | 10 mg | 3 mL | 3.33 |
| Melanotan II (10 mg Vial) | Single Peptide | 250 mcg–1 mg daily | Subcutaneous | Once daily (loading), 1-2 times weekly (maintenance) | 10 mg | 3 mL | 3.33 |
| MOTS-c (40 mg Vial) | Single Peptide | 200-1000 mcg daily | Subcutaneous | Once daily | 40 mg | 3 mL | 13.33 |
| NAD+ (500 mg Vial) | Single Peptide | 50-100 mg daily | Subcutaneous | Once daily | 500 mg | 3 mL | 166.7 |
| PE-22-28 (10 mg Vial) | Single Peptide | 50-200 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| PT-141 (10 mg Vial) | Single Peptide | 500-1500 mcg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| PT-141 + Melanotan II Stack (10 mg Vials) | Stack | PT-141: 750-1750 mcg on-demand; Melanotan II: 250-1000 mcg daily | Subcutaneous | PT-141: On-demand (max 1x/24h); Melanotan II: Once daily (loading), then 2-3x/week (maintenance) | 10 mg | 3 mL | 3.33 |
| Retatrutide (10 mg Vial) | Single Peptide | 2-12 mg weekly | Subcutaneous | Once weekly | 10 mg | 3 mL | 3.33 |
| Retatrutide (20 mg Vial) | Single Peptide | 2-12 mg weekly | Subcutaneous | Once weekly | 20 mg | 3 mL | 6.67 |
| Retatrutide (30 mg Vial) | Single Peptide | 2-12 mg weekly | Subcutaneous | Once weekly | 30 mg | 3 mL | 10 |
| Retatrutide (40 mg Vial) | Single Peptide | 2-12 mg weekly | Subcutaneous | Once weekly | 40 mg | 3 mL | 13.33 |
| Retatrutide (60 mg Vial) | Single Peptide | 2-12 mg weekly | Subcutaneous | Once weekly | 60 mg | 3 mL | 20 |
| Selank (10 mg Vial) | Single Peptide | 100-200 mcg per spray, 300-2700 mcg daily (variable) | Intranasal | Variable, often 1-3 times daily | 10 mg | 3 mL | 3.33 |
| Semaglutide (10 mg Vial) | Single Peptide | 250 mcg - 2.4 mg weekly | Subcutaneous | Once weekly | 10 mg | 3 mL | 3.33 |
| Semaglutide (20 mg Vial) | Single Peptide | 250 mcg - 2.4 mg weekly | Subcutaneous | Once weekly | 20 mg | 3 mL | 6.67 |
| Semaglutide (30 mg Vial) | Single Peptide | 250 mcg - 2.4 mg weekly | Subcutaneous | Once weekly | 30 mg | 3 mL | 10 |
| Semax (10 mg Vial) | Single Peptide | Not established for human injection | Injectable research (not validated in humans) | Not established | 10 mg | 3 mL | 3.333 |
| SS-31 (50 mg Vial) | Single Peptide | 5-10 mg daily | Subcutaneous | Once daily | 50 mg | 3 mL | 16.67 |
| TB-500 + BPC-157 Stack (10 mg Vials) | Stack | TB-500: 1250 mcg weekly; BPC-157: 250-500 mcg daily | Subcutaneous | TB-500: Once or twice weekly; BPC-157: Once daily | 10 mg | 3 mL | 3.33 |
| Tesamorelin (10 mg Vial) | Single Peptide | 1-2 mg daily | Subcutaneous | Once daily | 10 mg | 3 mL | 3.33 |
| Tirzepatide (10 mg Vial) | Single Peptide | 2.5-15 mg weekly | Subcutaneous | Once weekly | 10 mg | 3 mL | 3.33 |
| Tirzepatide (15 mg Vial) | Single Peptide | 2.5-15 mg weekly | Subcutaneous | Once weekly | 15 mg | 3 mL | 5 |
| Tirzepatide (20 mg Vial) | Single Peptide | 2.5-15 mg weekly | Subcutaneous | Once weekly | 20 mg | 3 mL | 6.67 |
| Tirzepatide (40 mg Vial) | Single Peptide | 2.5-15 mg once weekly | Subcutaneous | Once weekly | 40 mg | 3 mL | 13.33 |
| Tirzepatide (5 mg Vial) | Single Peptide | 2.5-15 mg weekly | Subcutaneous | Once weekly | 5 mg | 3 mL | 1.67 |
| Tirzepatide (60 mg Vial) | Single Peptide | 2.5-15 mg once weekly | Subcutaneous | Once weekly | 60 mg | 3 mL | 20 |
Showing 46 of 46 protocols. Concentrations assume the dilution listed on each protocol page.